Our Bourgoin facility is an FDA approved center of excellence for early and late-stage development and commercial manufacturing of Oral Solid Dose (OSD) products with a specialization in high potency API.
Early development hub
This new, 430-square-meter, dedicated research and development hub offers state-of-the art equipment and technologies to support formulation development and mature product characterization of oral solid dose form.
This enables our customers to get to market faster by making smarter decisions, minimizing experimental efforts and reducing risk.
Working in close collaboration with our Milton Park, UK site, Bourgoin provides fast, flexible small-scale manufacturing combined with robust full-scale processes. Bourgoin is our leading EU site for commercial manufacturing of oral solid dose products.
Areas of expertise include:
This site features a strong regulatory inspection history from all major international regulatory agencies. Additionally, we are also making continued investments in the site both in capital and scientific resources.
Learn more about the specific equipment and capabilities at this site by downloading our Site Fact Sheet.